<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:department>Infectious and Tropical Diseases</gtr:department><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6506A2B9-0242-4F99-BB83-6BE3FE99DE90"><gtr:id>6506A2B9-0242-4F99-BB83-6BE3FE99DE90</gtr:id><gtr:firstName>Taane</gtr:firstName><gtr:surname>Clark</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E15F7234-12BB-40F3-8C83-15875560EE3B"><gtr:id>E15F7234-12BB-40F3-8C83-15875560EE3B</gtr:id><gtr:firstName>Trevor</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Lawley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/77F021F2-CB59-421B-9A71-664FE2218FBD"><gtr:id>77F021F2-CB59-421B-9A71-664FE2218FBD</gtr:id><gtr:firstName>Munir</gtr:firstName><gtr:surname>Pirmohamed</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/072D7D18-370B-4237-AF08-E0C80323512F"><gtr:id>072D7D18-370B-4237-AF08-E0C80323512F</gtr:id><gtr:firstName>Fabio</gtr:firstName><gtr:surname>Miyajima</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C5408F79-E297-4CFB-9A94-977B26D51DB3"><gtr:id>C5408F79-E297-4CFB-9A94-977B26D51DB3</gtr:id><gtr:firstName>Brendan</gtr:firstName><gtr:surname>Wren</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FK000551%2F1"><gtr:id>2089D242-5FDC-4507-B577-82DE1522DBD7</gtr:id><gtr:title>The interactions between Clostridium difficile, intestinal microbiota and the host response in hospitalised patients</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K000551/1</gtr:grantReference><gtr:abstractText>Clostridium difficile is a bacterium that causes chronic diarrhoea and sometimes life-threatening disease (referred to as C. difficile infection or CDI) mainly in elderly and hospitalized patients. C. difficile is now the most significant hospital acquired infection with over 34,000 UK cases last year and an estimated cost to be &amp;pound;500 million per annum. The reported incidence of CDI has risen dramatically over the last decade and is related to the emergence of aggressive strains. Given the ability of C. difficile to evolve to be highly virulent coupled with the ageing population and increasing rates of hospitalization, the problem of CDI is likely to continue. It is a current NHS imperative to reduce the burden of CDI. 

CDI is unique among infections in that in almost all cases, disease follows the administration of antibiotics that disrupt the &amp;quot;normal&amp;quot; bacteria (called microbiota) present in the gut. It provides C. difficile the opportunity to overgrow, produce toxins and cause disease. It has become apparent that the balance of the microbiota plays a key role in disease. One of the most perplexing questions concerning CDI is the diversity of clinical symptoms. For example, C. difficile colonization can result in a spectrum of clinical outcomes ranging from asymptomatic carriage to death. The relative virulence of C. difficile organism clearly plays a role in determining clinical outcome, but the nature of this role has not been identified. Up to 30% of patients treated successfully for symptomatic CDI succumb to recurrent disease, but it is unclear why only some patients relapse. In addition to the pathogen, the host immune response and/or host microbiota are also likely important determinants of clinical outcome, but remain largely unexplored. Our central hypothesis is that variations in C. difficile genetics, the composition of the resident intestinal microbiota and the host immune response to the bacterium shape the clinical outcome. 

We will investigate the hree-way interaction between pathogen, host and microbiota by monitoring a unique group of patients with and without CDI. C. difficile serum and faecal samples will be studied in unprecedented detail to provide a platform for follow up studies to understand how C. difficile causes disease. We have established a high quality prospectively collected bioarchive comprising bacterial, blood and serum samples from 300 patients with CDI and full clinical history. These samples are linked to detailed clinical data and a disease severity-scoring index along with 150 control samples from hospitalised patients who have been exposed to antibiotics but did not develop CDI. We will use the existing cohort to validate methodologies and then also recruit another cohort of 150 confirmed CDI cases, 100 diarrhoea controls and 100 healthy volunteers (e.g. patient's spouses) to confirm our findings. This unique resource will be used to monitor the host response (including how the immune system responds to the infection), determine the complete genome sequence of infecting C. difficile and identify the intestinal microbiota by sequencing and culturing. The studies will also allow us to distinguish between re-infection (infection caused by another strain) and relapse (re-infection caused by the same strain). 

Robust statistical analysis comparing disease severity, host response, infecting pathogen and the composition of intestinal microbiota will facilitate subsequent studies on C. difficile to determine how and why it causes disease. This will be achieved by selecting C. difficile genes and constructing defined mutants and studying these alongside the parent strain in a range of assays established in the applicants' laboratories.

A comprehensive understanding of C. difficile, the host response and the intestinal microbiota will strengthen our understanding of the microorganism and to develop novel strategies to reduce the burden of CDI.</gtr:abstractText><gtr:technicalSummary>Reduction in C. difficile infection (CDI) related morbidity and mortality is a current healthcare imperative. To develop appropriate sustained interventions, a holistic integrated view of the pathogen, the host response and the intestinal microbiota during infection is required. Our central hypothesis is that variation in C. difficile genetics, the composition of the resident intestinal microbiota and the repertoire of host factors, including the humoral immune response, shape the clinical outcome of CDI. To this end we will evaluate in unprecendented detail the pathogen genome sequence, intestinal microbial composition and the host response in a case-control study of CDI hospitalised patients. Rigorous statistical comparisons of data from the organism, intestinal microbiota and host response in relation to a patient disease severity index will enable selected genes/proteins to be chosen for functional analysis. To determine their role, defined/complemented mutants and wild type strains will be compared in several relevant in vivo-relevant assays. Potential biomarkers of disease severity will be assessed based on the combined clinical and molecular profile. Additionally, we will identify key bacterial groups important in re-establishing healthy microbiota during infection. Such analysis will investigate the role of the microbiota in providing colonisation resistance against CDI and will give new information on the bacterial species important in the re-establishment of healthy microbiota after infection, with applications in the rational design of microbial replacement therapy. This integrated clinical case control study will provide for the first time a comprehensive comparison of the pathogen, host response and the role of the intestinal microbiota in CDI that will afford new clues to pathogenesis with practical implications in terms of diagnosis and therapeutic interventions.</gtr:technicalSummary><gtr:potentialImpactText>C. difficile is now known to be the most frequent cause of hospital acquired infections in developed countries. Given the continued use of broad-spectrum antibiotics, other drugs and the rising numbers of immuno-compromised and elderly patients, the problems associated with CDI will remain a challenge to healthcare delivery for the foreseeable future. To date, most research on C. difficile has been piecemeal and has not taken into account the role of the microbiota and the host. This study will uniquely follow infection in a cohort of patients and be compared to appropriate controls. This multidisciplinary research programme fits squarely into several priority research areas identified by the MRC, in terms of reducing the burden of hospital acquired infections, health in the ageing population, the application of genomics, to the identification of biomarkers, drug and vaccine candidate and the design of novel treatments.

Given the mortality and morbidity caused by CDI and the enormous cost to the UK economy (estimated to be &amp;pound;500 million per annum), the benefits of improved methods to detect, prevent and understand CDI to health and wealth of society are self-evident. The commercial private sector will potentially benefit from the research in several areas. Specific examples include the investigation of the role of the healthy microbiota in providing colonisation resistance against CDI and will give new information on the bacterial species important in the re-establishment of a healthy microbiota after infection, with applications in the rational design of microbial replacement therapy. The identification of immunodominant antigens from samples of patient serum with the pan-C.difficile protein microarray may identify useful immunodiagnostic markers and provide information on potential vaccine candidates. A deeper understanding of the factors important during relapse may provide clues to novel strategies to curtail the effect of CDI. Given the healthcare issues surronding hospital-acquired infections and the human microbiota, the project will also engage the public 

Additionally, through these studies and our deeper understanding of CDI and recurrent disease, this is likely to influence policy makers and regulators as to the optimum treatment for CDI. C. difficile and CDI are very much in the public and political eye, the co-ordinated program of work described is unique and promises to break new ground in both basic and translational research. The research program should give the UK a significant boost in this important and topical health care issue and will contribute significantly to the UK science base.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2419864</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia, 22-26th October 2013 (Andrew Swale and Fabio Miyajima)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4DD5CF35-7961-4288-BAF5-369EEE1AF9F9</gtr:id><gtr:impact>Presentation of 2 posters which attracted significant attention from the audience.

Interactions with several leading research groups represented in the field, access to most current expertise and trends in the field. Set up of strategic collaborations and access to new methodologies and materials, such as protein epitopes and immunogenic.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.clostridia.net/ClostPath.htm</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TV Broadcasts</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1DDC4958-6FC4-4F54-8FF9-C841CD701B69</gtr:id><gtr:impact>BBC Breakfast TV interview on vaccine design and antimicrobial resistance
BBC one interview on Campylobacter in Food chain
One Show BBC on antimicrobial resistance</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Steering Committee Meeting on Clostridium difficile infection (Royal Liverpool and Broadgreen Hospitals - NHS Trust)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9CFDEF5E-9D72-4665-9042-D12A606D5CA8</gtr:id><gtr:impact>Our team is frequently invited to take part of the meetings and provide regular updates of our research findings to the committee.
This interaction with NHS is highly beneficial for both parts and has assisted the Hospitals to shape their guidelines and keep CDI and other nosocomial infections under control.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia, 22-26th October 2013 -conference cast (Andrew Swale)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C025F3B7-43D5-43EC-B14C-4C10FF49B78F</gtr:id><gtr:impact>Conference Cast made by Scitable (Nature education group) in which one of the members of the team (Andrew Swale: PhD Student) shared his experience related to his research and attendance at the 8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia, 22-26th October 2013 in Australia.

Provided further insights for postgraduate students about the conference experience for a junior researcher. Requests for further contributions have been made.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>http://www.nature.com/scitable/blog/conferencecast/molecular_biology_pathogenesis_of_the</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>38E8074C-319C-49CC-AE06-75F8193287F9</gtr:id><gtr:impact>50-60 prospective undergraduate students attended the University open day with their parents, relatives and friends, and paid a visit to our research facilities. This was an important initiative to attract future talents for the courses offered in the area of biomedical sciences and medicine and the event as a whole has certainly sparked further interest from the audience as courses have been well sought after.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Academic Travel Award</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Santander Universities</gtr:fundingOrg><gtr:id>4928FFE1-5867-45EB-AFBA-229763D89986</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Science without Borders</gtr:department><gtr:description>Full PhD Fellowship</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Government of Brazil</gtr:fundingOrg><gtr:fundingRef>#200974442</gtr:fundingRef><gtr:id>7608B63C-A8B2-4DE7-8A4B-AA575C1B83C7</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Disruption of Clostridium difficile biofilms</gtr:description><gtr:id>0876A041-B8E7-4C06-9C1C-DB6AC8D99D95</gtr:id><gtr:impact>Simple treatment to reduce C. difficile disease</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>PCT/GB2013/051187</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Bacterial DNase compounds for treatment of biofilms</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/27273D4B-6697-4B59-AC8E-A19335A50501"><gtr:id>27273D4B-6697-4B59-AC8E-A19335A50501</gtr:id><gtr:title>Biomarkers for Clostridium difficile Infection: Challenges of deriving and implementing in research and clinical care</gtr:title><gtr:parentPublicationTitle>Clospath9</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/482d3b2888688e6d089b959ec62e3143"><gtr:id>482d3b2888688e6d089b959ec62e3143</gtr:id><gtr:otherNames>Miyajima F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6467E400-2A93-4548-BCFB-6C1BDFB1D92E"><gtr:id>6467E400-2A93-4548-BCFB-6C1BDFB1D92E</gtr:id><gtr:title>Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2b3ad74b2cbfefa8a45e2a92ee2f8910"><gtr:id>2b3ad74b2cbfefa8a45e2a92ee2f8910</gtr:id><gtr:otherNames>Coll F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2364B8E0-8E92-42F5-86E2-4F1A38D53573"><gtr:id>2364B8E0-8E92-42F5-86E2-4F1A38D53573</gtr:id><gtr:title>Role of Glycosyltransferases Modifying Type B Flagellin of Emerging Hypervirulent Clostridium difficile Lineages and Their Impact on Motility and Biofilm Formation.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0ab28b4b910418c280e90dbd622aed40"><gtr:id>0ab28b4b910418c280e90dbd622aed40</gtr:id><gtr:otherNames>Valiente E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/343DA87C-B931-4A4A-A01C-CF9B8D107923"><gtr:id>343DA87C-B931-4A4A-A01C-CF9B8D107923</gtr:id><gtr:title>Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e125de461f095e9031ebb2c359cafc78"><gtr:id>e125de461f095e9031ebb2c359cafc78</gtr:id><gtr:otherNames>Phelan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EDE87222-CFDD-4C7F-B07E-7A3D2B3E9A23"><gtr:id>EDE87222-CFDD-4C7F-B07E-7A3D2B3E9A23</gtr:id><gtr:title>Genomic Epidemiology of a Protracted Hospital Outbreak Caused by a Toxin A-Negative Clostridium difficile Sublineage PCR Ribotype 017 Strain in London, England.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ea7f3d8c3e172434e02195f264f9b9d9"><gtr:id>ea7f3d8c3e172434e02195f264f9b9d9</gtr:id><gtr:otherNames>Cairns MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1D9A9CB5-76EB-4D0A-AC54-9EEA46B9797E"><gtr:id>1D9A9CB5-76EB-4D0A-AC54-9EEA46B9797E</gtr:id><gtr:title>Health-Economic Evaluation of Clostridium Difficile Infection (Cdi) And Epidemiology In England And Merseyside.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/10f031052d961e069f64ecd0d6adbe4d"><gtr:id>10f031052d961e069f64ecd0d6adbe4d</gtr:id><gtr:otherNames>Nakamura CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/61BB9697-38A3-44B0-A54D-AC2CBCA5A4EF"><gtr:id>61BB9697-38A3-44B0-A54D-AC2CBCA5A4EF</gtr:id><gtr:title>Characterisation of circulating Clostridium difficile strains and mucosal inflammatory response in children with diarrhoea in Merseyside, UK</gtr:title><gtr:parentPublicationTitle>International Clostridium difficile Symposium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/31159a2534b75844aae1d8681d5d86f2"><gtr:id>31159a2534b75844aae1d8681d5d86f2</gtr:id><gtr:otherNames>Lees E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7C19CE4E-2329-434E-B2C5-CD6E3863A228"><gtr:id>7C19CE4E-2329-434E-B2C5-CD6E3863A228</gtr:id><gtr:title>Predicting poor disease outcomes of Clostridium difficile Infection: The quest for more answers?</gtr:title><gtr:parentPublicationTitle>International Clostridium difficile Symposium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/482d3b2888688e6d089b959ec62e3143"><gtr:id>482d3b2888688e6d089b959ec62e3143</gtr:id><gtr:otherNames>Miyajima F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/301CF952-7542-4128-854D-B85CF6A1B94E"><gtr:id>301CF952-7542-4128-854D-B85CF6A1B94E</gtr:id><gtr:title>Whole-genome scans provide evidence of adaptive evolution in Malawian Plasmodium falciparum isolates.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/99b6ba2bd2cbe0ae4f6cd822c693c7ce"><gtr:id>99b6ba2bd2cbe0ae4f6cd822c693c7ce</gtr:id><gtr:otherNames>Ocholla H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/709DFFF4-838B-472A-B9A4-6E082A862D49"><gtr:id>709DFFF4-838B-472A-B9A4-6E082A862D49</gtr:id><gtr:title>The Type B Flagellin of Hypervirulent Clostridium difficile Is Modified with Novel Sulfonated Peptidylamido-glycans.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad5e9a3c71bb147fa1eae321f4fc9a5a"><gtr:id>ad5e9a3c71bb147fa1eae321f4fc9a5a</gtr:id><gtr:otherNames>Bouch? L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7590028C-BB68-468C-A629-43CFFF985232"><gtr:id>7590028C-BB68-468C-A629-43CFFF985232</gtr:id><gtr:title>Further Evidence of Increasing Diversity of Plasmodium vivax in the Republic of Korea in Recent Years.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0ef082f96e626cce81f78fe979e8c994"><gtr:id>0ef082f96e626cce81f78fe979e8c994</gtr:id><gtr:otherNames>Kim JY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A81E8BD5-D5E9-4D9F-A2C2-7260DFBD0D10"><gtr:id>A81E8BD5-D5E9-4D9F-A2C2-7260DFBD0D10</gtr:id><gtr:title>African glucose-6-phosphate dehydrogenase alleles associated with protection from severe malaria in heterozygous females in Tanzania.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/04b51454b7779504ab271ad8bae5b911"><gtr:id>04b51454b7779504ab271ad8bae5b911</gtr:id><gtr:otherNames>Manjurano A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E341EDD8-F17E-466E-B0C5-F2803B26D704"><gtr:id>E341EDD8-F17E-466E-B0C5-F2803B26D704</gtr:id><gtr:title>Towards a host biomarker profiling strategy for Clostridium difficile infection (CDI)</gtr:title><gtr:parentPublicationTitle>8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia, 22-26th October 2013.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eb035f2d90de591ab39a584bfbfc365c"><gtr:id>eb035f2d90de591ab39a584bfbfc365c</gtr:id><gtr:otherNames>Miyajima, F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/950ED7CD-C085-4F6D-A6F1-FF3FD044C7D4"><gtr:id>950ED7CD-C085-4F6D-A6F1-FF3FD044C7D4</gtr:id><gtr:title>Imputation-based population genetics analysis of Plasmodium falciparum malaria parasites.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c02077ca0782a27d22d4a42628bbac0b"><gtr:id>c02077ca0782a27d22d4a42628bbac0b</gtr:id><gtr:otherNames>Samad H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/19C1F157-2F30-4209-A958-7FD9CF279B83"><gtr:id>19C1F157-2F30-4209-A958-7FD9CF279B83</gtr:id><gtr:title>Conjunctival fibrosis and the innate barriers to Chlamydia trachomatis intracellular infection: a genome wide association study.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/32b758852c71a2a364d543a80f877171"><gtr:id>32b758852c71a2a364d543a80f877171</gtr:id><gtr:otherNames>Roberts Ch</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FFEE2FE1-8E83-47C3-914F-AB1FCF61FEC1"><gtr:id>FFEE2FE1-8E83-47C3-914F-AB1FCF61FEC1</gtr:id><gtr:title>Is the interleukin 8 promoter polymorphism rs4073/-251T &amp;gt;A associated with Clostridium difficile infection?</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/482d3b2888688e6d089b959ec62e3143"><gtr:id>482d3b2888688e6d089b959ec62e3143</gtr:id><gtr:otherNames>Miyajima F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB958B1B-735D-475B-A271-4B02706A4274"><gtr:id>AB958B1B-735D-475B-A271-4B02706A4274</gtr:id><gtr:title>Improved bacterial mutagenesis by high-frequency allele exchange, demonstrated in Clostridium difficile and Streptococcus suis.</gtr:title><gtr:parentPublicationTitle>Applied and environmental microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dd35f3753b466bcc441f04bb01804c31"><gtr:id>dd35f3753b466bcc441f04bb01804c31</gtr:id><gtr:otherNames>Faulds-Pain A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0099-2240</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41B98BB5-3578-4C7D-8EC2-B2C70DF5BAE2"><gtr:id>41B98BB5-3578-4C7D-8EC2-B2C70DF5BAE2</gtr:id><gtr:title>Serum mannose-binding lectin concentration, but not genotype, is associated with Clostridium difficile infection recurrence: a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/457947f364d47f74402a3480a442e478"><gtr:id>457947f364d47f74402a3480a442e478</gtr:id><gtr:otherNames>Swale A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/79A0A115-A00F-40C5-82E0-4DFDE2A1BCED"><gtr:id>79A0A115-A00F-40C5-82E0-4DFDE2A1BCED</gtr:id><gtr:title>Genomic variation in two gametocyte non-producing Plasmodium falciparum clonal lines.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/74857d2b9bd60c065bebd0bd630bb80d"><gtr:id>74857d2b9bd60c065bebd0bd630bb80d</gtr:id><gtr:otherNames>Campino S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53594BA0-78EA-4E18-AD9C-F42DDB287C2C"><gtr:id>53594BA0-78EA-4E18-AD9C-F42DDB287C2C</gtr:id><gtr:title>Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/457947f364d47f74402a3480a442e478"><gtr:id>457947f364d47f74402a3480a442e478</gtr:id><gtr:otherNames>Swale A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8998F7BA-8A7D-446C-8A00-152FB8A4AB6A"><gtr:id>8998F7BA-8A7D-446C-8A00-152FB8A4AB6A</gtr:id><gtr:title>Clostridium difficile has a single sortase, SrtB, that can be inhibited by small-molecule inhibitors.</gtr:title><gtr:parentPublicationTitle>BMC microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8128f5f706406d62dea46a152d299689"><gtr:id>8128f5f706406d62dea46a152d299689</gtr:id><gtr:otherNames>Donahue EH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2180</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/06F47CF7-9259-4795-B07E-11EBAA7B8EED"><gtr:id>06F47CF7-9259-4795-B07E-11EBAA7B8EED</gtr:id><gtr:title>A proportion of mutations fixed in the genomes of in vitro selected isogenic drug-resistant Mycobacterium tuberculosis mutants can be detected as minority variants in the parent culture.</gtr:title><gtr:parentPublicationTitle>FEMS microbiology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/400f9f8391b83dd2b92949d8b1068c24"><gtr:id>400f9f8391b83dd2b92949d8b1068c24</gtr:id><gtr:otherNames>Bergval I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0378-1097</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BEC6F798-8DCD-468B-8F93-0EF90E1F5E13"><gtr:id>BEC6F798-8DCD-468B-8F93-0EF90E1F5E13</gtr:id><gtr:title>Clostridium difficile modulates host innate immunity via toxin-independent and dependent mechanism(s).</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/16da9594eedf0f15c85fe9f971d8e9c9"><gtr:id>16da9594eedf0f15c85fe9f971d8e9c9</gtr:id><gtr:otherNames>Jafari NV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3CEACE61-4B3B-4736-B69F-39E603C9EDCE"><gtr:id>3CEACE61-4B3B-4736-B69F-39E603C9EDCE</gtr:id><gtr:title>Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/379d2cbad76529bd962a1dda2883c79b"><gtr:id>379d2cbad76529bd962a1dda2883c79b</gtr:id><gtr:otherNames>Abdallah AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/02422161-6CFE-4E83-BC09-0F75B2C4B6CE"><gtr:id>02422161-6CFE-4E83-BC09-0F75B2C4B6CE</gtr:id><gtr:title>Predominance of PCR-ribotypes, 018 (smz) and 369 (trf) of Clostridium difficile in Japan: a potential relationship with other global circulating strains?</gtr:title><gtr:parentPublicationTitle>Journal of medical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0d9caf86d170c71060fb8bce10a6a001"><gtr:id>0d9caf86d170c71060fb8bce10a6a001</gtr:id><gtr:otherNames>Senoh M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-2615</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D88887D8-D139-44AB-B5B0-8A2B32BB7979"><gtr:id>D88887D8-D139-44AB-B5B0-8A2B32BB7979</gtr:id><gtr:title>Glucose-6-phosphate dehydrogenase polymorphisms and susceptibility to mild malaria in Dogon and Fulani, Mali.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/311f5170e30802e247a129d0bc9c7053"><gtr:id>311f5170e30802e247a129d0bc9c7053</gtr:id><gtr:otherNames>Maiga B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6438C484-6E9B-436B-9BB0-06483BFA4E7C"><gtr:id>6438C484-6E9B-436B-9BB0-06483BFA4E7C</gtr:id><gtr:title>The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move.</gtr:title><gtr:parentPublicationTitle>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0ab28b4b910418c280e90dbd622aed40"><gtr:id>0ab28b4b910418c280e90dbd622aed40</gtr:id><gtr:otherNames>Valiente E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1198-743X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/510228EA-4036-4D5E-9395-6A912BBB45BC"><gtr:id>510228EA-4036-4D5E-9395-6A912BBB45BC</gtr:id><gtr:title>Recombination in pe/ppe genes contributes to genetic variation in Mycobacterium tuberculosis lineages.</gtr:title><gtr:parentPublicationTitle>BMC genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3ba3a7d68cb58d8b1f7a949a40729d3d"><gtr:id>3ba3a7d68cb58d8b1f7a949a40729d3d</gtr:id><gtr:otherNames>Phelan JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2164</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/21DA047F-2E83-4D54-A671-0FF617B9150A"><gtr:id>21DA047F-2E83-4D54-A671-0FF617B9150A</gtr:id><gtr:title>Emergence and global spread of epidemic healthcare-associated Clostridium difficile.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3056b899bd6dafc64c0b2150e4f403d5"><gtr:id>3056b899bd6dafc64c0b2150e4f403d5</gtr:id><gtr:otherNames>He M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9D649E96-9B01-42C3-8976-BB24B192DFBC"><gtr:id>9D649E96-9B01-42C3-8976-BB24B192DFBC</gtr:id><gtr:title>The draft genome of Mycobacterium aurum, a potential model organism for investigating drugs against Mycobacterium tuberculosis and Mycobacterium leprae.</gtr:title><gtr:parentPublicationTitle>International journal of mycobacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e125de461f095e9031ebb2c359cafc78"><gtr:id>e125de461f095e9031ebb2c359cafc78</gtr:id><gtr:otherNames>Phelan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2212-5531</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3E2A95C9-5D44-4648-98BA-B68F07C68A89"><gtr:id>3E2A95C9-5D44-4648-98BA-B68F07C68A89</gtr:id><gtr:title>Association of faecal Lactoferrin and Calprotectin in a prospective Clostridium difficile infection (CDI) cohort</gtr:title><gtr:parentPublicationTitle>8th International Conference on the Molecular Biology and Pathogenesis of the Clostridia, 22-26th October 2013. Abstract 56, Page 43</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cfb33177bce5df4d3fdcfebd658f4e60"><gtr:id>cfb33177bce5df4d3fdcfebd658f4e60</gtr:id><gtr:otherNames>Swale, A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/87A7951D-7D88-4E06-9B8C-974B659BE1CE"><gtr:id>87A7951D-7D88-4E06-9B8C-974B659BE1CE</gtr:id><gtr:title>Is the interleukin 8 promoter polymorphism rs4073/-251T &amp;gt;A associated with Clostridium difficile infection?</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/482d3b2888688e6d089b959ec62e3143"><gtr:id>482d3b2888688e6d089b959ec62e3143</gtr:id><gtr:otherNames>Miyajima F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/05B7FD79-3551-4707-A41F-374E73E5A3AC"><gtr:id>05B7FD79-3551-4707-A41F-374E73E5A3AC</gtr:id><gtr:title>Comparative Genome Analysis and Global Phylogeny of the Toxin Variant Clostridium difficile PCR Ribotype 017 Reveals the Evolution of Two Independent Sublineages.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ea7f3d8c3e172434e02195f264f9b9d9"><gtr:id>ea7f3d8c3e172434e02195f264f9b9d9</gtr:id><gtr:otherNames>Cairns MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/080754D0-DA87-4E80-BCE5-630EB7686AD1"><gtr:id>080754D0-DA87-4E80-BCE5-630EB7686AD1</gtr:id><gtr:title>Genome-Based Infection Tracking Reveals Dynamics of Clostridium difficile Transmission and Disease Recurrence.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e8f6e2b589637133576bc99ec570b25b"><gtr:id>e8f6e2b589637133576bc99ec570b25b</gtr:id><gtr:otherNames>Kumar N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/950E71C2-8064-4E69-A19F-60BEA402D409"><gtr:id>950E71C2-8064-4E69-A19F-60BEA402D409</gtr:id><gtr:title>Population genomic structure and adaptation in the zoonotic malaria parasite Plasmodium knowlesi.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1e07eaea1db731f436f85f87b1c89fdd"><gtr:id>1e07eaea1db731f436f85f87b1c89fdd</gtr:id><gtr:otherNames>Assefa S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8E61FD91-42A9-420E-82A6-639D81CDFF72"><gtr:id>8E61FD91-42A9-420E-82A6-639D81CDFF72</gtr:id><gtr:title>USP38, FREM3, SDC1, DDC, and LOC727982 Gene Polymorphisms and Differential Susceptibility to Severe Malaria in Tanzania.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/04b51454b7779504ab271ad8bae5b911"><gtr:id>04b51454b7779504ab271ad8bae5b911</gtr:id><gtr:otherNames>Manjurano A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K000551/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>